Parasitic worms are difficult to kill with current therapies, but their commensal bacteria might be their Achilles’ heel.

Disinfectants induce oxidative damage in bacteria, but a single mutation triggers the expression of genes that help the ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary ...

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases: Hamburg, Germany Thursday, January 23, 2025, 10:00 Hrs [IST] Evotec SE, ...

Institute of Agrobiological Sciences, National Agriculture and Food Research Organization (NARO), 1-2 Owashi, Tsukuba, Ibaraki 305-8634, Japan ...

Evolution of pyrrolysyl-tRNA synthetase (PylRS) for diBrK. Credit: Proceedings of the National Academy of Sciences (2024). DOI: 10.1073/pnas.2415220121 ...

Oxford Drug Design's platform integrates pioneering generative AI capabilities with tRNA synthetase expertise, including proprietary structural biology. The firm said the new data shows the potential ...

Oxford Drug Design’s advances are enabled by its dual-competence discovery platform. This platform integrates generative AI capabilities with tRNA synthetase expertise, including proprietary ...

Oxford Drug Design’s rapid advances have been enabled by its distinctive dual-competence discovery platform integrating pioneering generative AI capabilities with tRNA synthetase expertise, including ...

ATyr Pharma is using its proprietary tRNA synthetase platform, which includes a library of domains derived from all 20 tRNA synthetases, to develop new therapies for fibrosis and inflammation.